Solascure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers

SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation…

Continue ReadingSolascure receives FDA Fast Track Designation for Aurase Wound Gel to treat calciphylaxis ulcers